Apogee Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Thomas Henderson
- Full Time Employees
- 261
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 221 Crescent Street Waltham MA United States of America 02453
- IPO Date
- Jul 14, 2023
- CIK
- 0001974640
- Website
- apogeetherapeutics.com
- Similar Companies
- Business
- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company founded in 2022 and headquartered in Waltham, Massachusetts, develops novel biologics targeting inflammatory and immunological diseases, including atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other immune-mediated conditions; its lead product candidate, APG777, comprises a subcutaneous extended half-life monoclonal antibody (mAb) against IL-13 in Phase 2 trials for AD and Phase 1 trials for asthma and EoE; APG279 targets OX40L in preclinical development for AD; APG990 offers an SQ extended half-life mAb for AD; APG333 constitutes a human mAb against thymic stromal lymphopoietin for asthma and COPD; APG808 provides an SQ extended half-life mAb targeting IL-4Rα for Type 2 allergic diseases. The company operates primarily in the United States with a workforce of approximately 196 employees focused on advancing monotherapies and combinations to achieve best-in-class efficacy and dosing convenience for patients underserved by current standards of care in dermatology, respiratory, and gastroenterological segments. In recent developments, Apogee Therapeutics closes a $345 million follow-on equity financing in October 2025 to support clinical pipeline advancement into 2028; it progresses the Phase 2 APEX trial of APG777 in AD with Part A fully enrolled and interim 16-week data expected mid-2025 alongside Part B enrollment; the company doses the first patient in a Phase 1b asthma trial for APG777, reports positive interim APG808 results showing 53% FeNO reduction in asthma, and plans a head-to-head Phase 1b trial of APG279 versus Dupixent in AD later in 2025.
Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?
Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?
Biotech ETF Index Surges 10% After Rebalance
Is AbbVie a Buy After Its Purchase of Apogee?
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
Here Are Wednesday’s Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More
Nova Minerals redomiciles to US as Alaska gold and antimony work accelerates
G50 Corp strikes high-grade gold at first White Caps core hole in Nevada
Empire Metals to host investor presentation on Pitfield progress
Metals One builds 5.57% stake in newly listed Talon Resources
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apogee Therapeutics, Inc. (NASDAQ: APGE)
Nasdaq slides but Dow closes higher as investors ditch megacap tech